Medicare open enrollment began Thursday, marking the start of a period where beneficiaries must choose between traditional Medicare, Medicare Advantage plans, and prescription drug coverage for the upcoming year. Changes taking effect on Jan. 1, 2027, include increased out-of-pocket limits for Part D drugs, the expiration of temporary federal premium subsidies, and the implementation of new government-negotiated prices for 15 specific medications.
The enrollment window remains open until Dec. 7. This cycle coincides with the Social Security Administration's announcement that the annual cost-of-living adjustment (COLA) for retirees and people with disabilities will rise by 3.6% in 2027. This adjustment translates to an average increase of $75 per month for the nearly 72 million people receiving Social Security benefits.
What the Left Is Saying
Advocates for the new drug pricing measures point to the Biden-era legislation that enabled Medicare to negotiate costs as a critical step in reducing long-term healthcare expenditures. The Centers for Medicare & Medicaid Services (CMS) projects that the new negotiated prices for 15 drugs, including weight-loss and diabetes medications such as Ozempic, Rybelsus, and Wegovy, will lower prescription drug coverage costs for Medicare enrollees by $685 million in 2027.
Progressive voices highlight that these changes stem from the Inflation Reduction Act, which established the framework for federal drug price negotiations. The addition of these 15 drugs to the negotiation list is viewed by supporters as a direct response to high out-of-pocket costs for common chronic conditions. The expiration of the temporary Part D subsidy, which was implemented by the Biden administration in 2024 to mitigate the immediate effects of the law, is seen by some analysts as a planned phase-out rather than a new austerity measure, as the underlying price negotiations are expected to provide structural relief.
What the Right Is Saying
The Trump administration has emphasized its recent executive actions to provide immediate financial relief to seniors, framing the $90 one-time payments for Part B premiums as a direct benefit to enrollees. President Donald Trump stated that his administration would issue these payments to help more than 20 million Medicare enrollees, costing approximately $2 billion. The administration argues that these rebates, along with $500 rebate checks for roughly 1 million Affordable Care Act premium payers, demonstrate a commitment to lowering costs for those currently enrolled.
Critics within the conservative sphere and some policy analysts note that the $90 rebate excludes approximately 35 million Medicare Advantage enrollees, as well as many individuals with disabilities and low-income beneficiaries. The administration contends that the exclusion of Medicare Advantage participants is due to the different structure of those private plans, which often include Part B premiums in their overall cost-sharing. The end of the temporary Part D premium subsidy is presented by the administration as a return to standard fiscal policy, with CMS projecting only modest price increases for most people in the coming year.
What the Numbers Show
For 2027, the annual out-of-pocket cap for Medicare Part D drugs will increase to $2,400, up from $2,100 in 2026. The standard Part D deductible will also rise from $615 to $700. The Social Security COLA increase of 3.6% will affect nearly 72 million Social Security beneficiaries and about 7.3 million Supplemental Security Income recipients.
The new Medicare-negotiated prices cover 15 drugs, including Ozempic, Rybelsus, Wegovy, Trelegy Ellipta, Xtandi, Pomalyst, Ibrance, Ofev, Linzess, Calquence, Austedo/Austedo XR, Breo Ellipta, Tradjenta, Xifaxan, Vraylar, Janumet/Janumet XR, and Otezla. CMS estimates these negotiations will reduce costs by $685 million for enrollees in 2027. The Trump administration's $90 Part B rebate is limited to about 20 million traditional Medicare enrollees, excluding the 35 million in Medicare Advantage plans.
The Bottom Line
Beneficiaries are urged to review their options carefully during the enrollment period, as the combination of higher deductibles, increased out-of-pocket caps, and the removal of temporary subsidies creates a more complex financial landscape for 2027. AARP Executive Vice President Nancy LeaMond noted that higher healthcare costs are making it harder for older Americans to afford care, emphasizing the importance of comparing coverage options. With midterm elections approaching, cost-of-living remains a primary concern for voters, making the impact of these Medicare changes a significant factor in public sentiment regarding healthcare policy.